Breaking News Instant updates and real-time market news.

MCD

McDonald's

$193.93

-2.71 (-1.38%)

, UAA

Under Armour

$21.16

0.51 (2.47%)

09:04
11/04/19
11/04
09:04
11/04/19
09:04

Fly Intel: Pre-market Movers

HIGHER: Wright Medical (WMGI), up 31% after Stryker (SYK) announced a definitive agreement to acquire all of the issued and outstanding ordinary shares of the company for $30.75 per share, or a total equity value of approximately $4B and a total enterprise value of approximately $5.4B. UP AFTER EARNINGS: Obsidian Energy (OBE), up 9%... Karyopharm (KPTI), up 12%... Bausch Health (BHC), up 2%... Evolus (EOLS), up 7%. DOWN AFTER EARNINGS: Ceragon Networks (CRNT), down 16%... Trevana (TRVN), down 7%. ALSO LOWER: Under Armour (UAA), down 14% after the Wall Street Journal reported both the Justice Department and the Securities and Exchange Commission are investigating the company's accounting practices. Under Armour also reported Q3 results this morning and cut its FY19 revenue growth guidance... McDonald's (MCD), down 2% after firing CEO Steve Easterbrook following the board's determination that "he violated company policy and demonstrated poor judgment involving a recent consensual relationship with an employee"... Aveo Pharmaceuticals (AVEO), down 40% after the FDA said that the company's current interim OS results from the TIVO-3 trial do not abrogate the FDA's concerns over detriment and that those results may worsen with final analysis at 263 events and that the median OS for tivozanib is worse than that of sorafenib... Stryker (SYK), down 3% after announcing the planned acquisition of Wright Medical.

MCD

McDonald's

$193.93

-2.71 (-1.38%)

UAA

Under Armour

$21.16

0.51 (2.47%)

SYK

Stryker

$212.78

-3.5 (-1.62%)

WMGI

Wright Medical

$22.00

1.2 (5.77%)

AVEO

Aveo Pharmaceuticals

$0.89

-0.0119 (-1.31%)

OBE

Obsidian Energy

$0.62

0.0039 (0.64%)

KPTI

Karyopharm

$12.57

0.86 (7.34%)

BHC

Bausch Health

$25.92

1.07 (4.31%)

EOLS

Evolus

$15.89

(0.00%)

CRNT

Ceragon Networks

$2.96

-0.02 (-0.67%)

TRVN

Trevena

$1.01

0.0339 (3.49%)

UA

Under Armour

$18.91

0.41 (2.22%)

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 04

    Nov

  • 07

    Dec

MCD McDonald's
$193.93

-2.71 (-1.38%)

11/04/19
LEHM
11/04/19
NO CHANGE
Target $225
LEHM
Overweight
McDonald's should be bought on weakness from CEO change, says Barclays
While the CEO transition announced by McDonald's was unexpected, "and therefore not a good thing," the change was not due to operational or financial issues, but rather personal conduct, Barclays analyst Jeffrey Bernstein tells investors in a research note. The analyst is confident the company has the depth in leadership to maintain momentum as the global quick service restaurant leader. As such, he's a buyer of McDonald's shares on any weakness and keeps an Overweight rating on the name with a $225 price target.
11/04/19
FBCO
11/04/19
NO CHANGE
Target $230
FBCO
Outperform
Credit Suisse views any pullback in McDonald's stock as buying opportunity
Credit Suisse analyst Lauren Silberman tells investors in a research note that she thinks McDonald's shares could be under "modest" pressure Monday after the company announced that Steve Easterbrook has separated from the company following the board's determination that he violated company policy and demonstrated poor judgment involving a recent consensual relationship with an employee. Easterbrook was "highly regarded" in the investment community and among franchisees, and potential concerns of franchisee sentiment regarding new leadership, Silberman says, but adds that McDonald's has a "talented" bench and expects management and the board have a like-minded strategy. She says the management transition does not alter her positive view of the company, and views any material pullback pullback in the stock around the CEO change as a buying opportunity. Silberman maintains an Outperform rating and $230 price target.
11/04/19
SPHN
11/04/19
NO CHANGE
Target $225
SPHN
Overweight
McDonald's shares attractive on the pullback, says Stephens
The departure of CEO Steve Easterbrook is a "fairly significant negative" for investors, given his history of impressive and consistent global results, Stephens analyst Will Slabaugh tells investors in a research note. The analyst, however, likes the "quick choice" of Chris Kempczinski as the next CEO, given his existing relationships with domestic operators and "leadership experience during some of the U.S.'s best years in decades." Slabaugh likes McDonald's here and views the shares as attractive on the recent pullback. He keeps an Overweight rating on the name with a $225 price target. McDonald's in premarket trading is down 3%, or $5.09, to $188.85.
11/04/19
PIPR
11/04/19
DOWNGRADE
Target $195
PIPR
Neutral
McDonald's downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan downgraded McDonald's (MCD) to Neutral from Overweight with a price target of $195, down from $224. The stock in premarket trading is down 2%, or $4.35, to $189.59 after CEO Steve Easterbrook was let go due to a consensual relationship with employee. While the company's fundamentals are solid, CEO changes "of this magnitude tend to be disruptive," Regan tells investors in a research note. As such, the analyst is taking a "more cautionary view" on the shares, noting the potential lack of momentum and time involved in formalizing a new management team. She recommends a rotation into Chipotle Mexican Grill (CMG) shares.
UAA Under Armour
$21.16

0.51 (2.47%)

10/23/19
SBSH
10/23/19
NO CHANGE
SBSH
Buy
CEO change positive for Under Armour story, says Citi
Citi analyst Paul Lejuez views the announcement that President and COO Patrik Frisk will replace Kevin Plank as Under Armour CEO, effective January 1, as a positive for the story. Frisk has been pivotal in helping the organization "grow up" by focusing more on profitability, Lejuez tells investors in a research note. He believes investors are getting the "best of both worlds," with Frisk in charge of the day-to- day and Plank still playing an important role as the face of the brand. Lejuez keeps a Buy rating on Under Armour shares.
10/09/19
JEFF
10/09/19
NO CHANGE
JEFF
Buy
Under Armour product selling out, discounting is down, says Jefferies
Jefferies analyst Randal Konik says his September webscrapes illustrate that the overall athletic category "remains very strong." The highlight is Under Armour's (UAA) percentage of product on discount, which was down for each month in Q3 with strength coming from the HOVR platform, Konik tells investors in a research note. He believes the company's product is selling out, discounting is down, and inventory is controlled. Data also revealed traction in the Adidas (ADDYY) Ultraboost at retail, and Nike (NKE) "increasingly dominating" the secondary market with Jordan and Air Force platforms, says the analyst.
09/25/19
JEFF
09/25/19
NO CHANGE
Target $97
JEFF
Hold
Nike price target raised to $97 from $80 at Jefferies
Jefferies analyst Randal Konik raised his price target for Nike (NKE) to $97 from $80 saying the "broad-based, strong" 10% constant currency growth in last night's Q1 illustrates the ongoing power of its brand. However, these positives are fully contemplated in the shares at current levels, Konik tells investors in a post-earnings research note. The analyst, who prefers shares of Foot Locker (FL) and Under Armour (UAA), keeps a Hold rating on Nike.
09/12/19
PIPR
09/12/19
NO CHANGE
PIPR
Overweight
Under Armour checks show promotions tracking below last year, says Piper Jaffray
Piper Jaffray analyst Erinn Murphy says her channel checks quarter-to-date suggest promotional activity for Under Armour (UAA) continues to track slightly below last year's levels and that new product is resonating well. With her price target of $30 offering 40% upside from current levels, the analyst is revisiting the shares as a "favorite name" into Q4. Under Armour is more focused against a "cleaner" athletic backdrop and incremental innovation in apparel and footwear should accelerate in 2020, Murphy tells investors in a research note. She keeps an Overweight rating on the name.
SYK Stryker
$212.78

-3.5 (-1.62%)

11/04/19
PIPR
11/04/19
DOWNGRADE
Target $30.75
PIPR
Neutral
Wright Medical downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien downgraded Wright Medical Group (WMGI) to Neutral from Overweight with a price target of $30.75, up from $27. Given the size of Stryker's (SYK) buyout and "distracted competitors," the analyst does not anticipate another offer will come in over-the-top. O'Brien, however, thinks there is likely to be a lengthy Federal Trade Commission review, and he expects divestitures will be needed. He believes there will be several interested parties in any divested assets, so he does not expect finding buyers will hold up the transaction. O'Brien likes the deal for Stryker, saying it provides the company with the best portfolio of extremities products in the industry. He maintains an Overweight rating on Stryker.
09/05/19
ADAM
09/05/19
NO CHANGE
Target $233
ADAM
Buy
Stryker M&A activity viewed positively, says Canaccord
Canaccord analyst Kyle Rose noted Stryker agreed to acquire an imaging and robotics company which put them deeper into the spine business and complement their broader portfolio of robotic and navigation offerings which Rose believes is the future of spine surgery. Rose views the moves positively and views Stryker as a compelling asset. Rose reiterated his Buy rating and $233 price target on Stryker shares.
09/04/19
PIPR
09/04/19
NO CHANGE
PIPR
Overweight
Piper says robotics entry can accelerate Stryker's spine implant pull-through
After Stryker announced the purchase of Mobius Imaging and Cardan Robotics for $370M upfront and $130M in potential future milestones, Piper Jaffray analyst Matt O'Brien said he believes that having a robotics offering should accelerate implant pull-through for the company's Spine division. The analyst, who also sees the deals helping Stryker to present a more complete offering to customers once commercially available, keeps an Overweight rating on the stock.
07/26/19
ADAM
07/26/19
NO CHANGE
Target $233
ADAM
Buy
Stryker price target raised to $233 from $195 at Canaccord
Canaccord analyst Kyle Rose raised his price target on Stryker to $233 from $195 following strong Q2 results. The analyst said there was momentum across the entire portfolio and operationally, its earnings reflected strong sales growth and operating expense improvements. Rose reiterated his Buy rating on Stryker shares.
WMGI Wright Medical
$22.00

1.2 (5.77%)

11/04/19
CANT
11/04/19
NO CHANGE
Target $28
CANT
Overweight
Wright Medical buyout long part of investment thesis, says Cantor Fitzgerald
A potential takeout has long been part of Wright Medical Group's investment thesis since current CEO Bob Palmisano took over leadership of the company in 2011, Cantor Fitzgerald analyst Craig Bijou tells investors in a research note. As such, he is "somewhat hesitant" to believe that Friday's report from Bloomberg regarding a potential sale is different from the prior occasions. With that said, the analyst says Medtech transactions over the last five years suggest a multiple of four-to-five times forward sales. Wright is an attractive asset, but there are likely several considerations for potential buyers, says Bijou, who keeps an Overweight rating on the shares with a $28 price target.
11/03/19
STFL
11/03/19
NO CHANGE
STFL
Stifel agrees with report saying Wright Medical may be evaluating options
Stifel analyst Mathew Blackman, who has a Buy rating and $30 price target on Wright Medical Group (WMGI), said that Bloomberg reported late Friday that Wright Medical had engaged financial advisers to explore a potential sale of the company. While the analyst noted that it is impossible to confirm that report, he sees "legitimate reasons to believe the company is potentially evaluating strategic options," including its significant share underperformance, lack of a clear CEO succession plan, and that the shares are "undervalued relative to the company's leading position in attractive end markets with a robust profitability profile."
09/09/19
BOFA
09/09/19
NO CHANGE
BOFA
Generac added to Endeavor List, Wright Medical removed at BofA/Merrill
AVEO Aveo Pharmaceuticals
$0.89

-0.0119 (-1.31%)

03/28/19
NATL
03/28/19
INITIATION
NATL
Sell
Aveo Pharma initiated with a Sell, $0 price target at National Securities
National Securities initiated Aveo Pharmaceuticals with a Sell and $0 price target saying recent share appreciation is "totally unwarranted." The firm's analyst expects interim and final Phase 3 overall survival data updates to fail to support a Tivozanib NDA filing.
04/04/19
PIPR
04/04/19
NO CHANGE
Target $3
PIPR
Overweight
Piper maintains Overweight rating, $3 target on Aveo after stock sale
Piper Jaffray analyst Edward Tenthoff maintains his Overweight rating and $3 price target on Aveo Pharmaceuticals after the company "opportunistically" raised $25M by issuing 21.7M shares at $1.15 per share and 21.7M in warrants with a $1.25 strike price. The analyst, who estimates that Aveo now holds pro forma cash of about $57M, said the primary driver for the stock remains the OS analysis for TIVO-3 that is scheduled to be reported in Q4. If the hazard ratio does not drop to less than 1.0 for tivozanib, Tenthoff does not believe the FDA will accept a new NDA filing, he noted.
09/11/19
HCWC
09/11/19
UPGRADE
Target $1.75
HCWC
Buy
Aveo Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth upgraded Aveo Pharmaceuticals to Buy from Neutral and raised his price target for the shares to $1.75 from $1.00. The company yesterday provided an update from the ongoing Phase 3 Tivo-3 study of tivozanib for the treatment of advanced renal cell carcinoma that showed an improved overall survival hazard ratio of 0.99 compared to 1.12 reported back in February, Ramakanth tells investors in a research note. The analyst is encouraged and believes tivozanib could back on track for U.S. regulatory approval in 2021.
09/10/19
PIPR
09/10/19
NO CHANGE
Target $4
PIPR
Overweight
Aveo Pharmaceuticals price target raised to $4 from $3 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Aveo Pharmaceuticals to $4 from $3 after the company announced that tivozanib's overall survival hazard ratio was 0.99 as of a planned analysis on August 15. The analyst continues to anticipate launch in the 3rd and 4th-line renal cell carcinoma setting in 2021. The analyst reduced his tivozanib discount rate and keeps an Overweight rating on shares of Aveo Pharmaceuticals.
OBE Obsidian Energy
$0.62

0.0039 (0.64%)

09/10/19
RAJA
09/10/19
DOWNGRADE
RAJA
Underperform
Obsidian Energy downgraded to Underperform from Market Perform at Raymond James
KPTI Karyopharm
$12.57

0.86 (7.34%)

09/24/19
BARD
09/24/19
NO CHANGE
Target $25
BARD
Outperform
Karyopharm Xpovio launch appears strong, says Baird
Baird analyst Michael Ulz said his physician survey regarding the Karyopharm launch of Xpovio is indicating strong early trends. The analyst said there appears to be an early robust, broad adoption with meaningful share gains ahead, and the safety profile is manageable. Ulz said he sees upside to estimates and he reiterated his Outperform rating and $25 price target on Karyopharm shares.
07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
Karyopharm upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst says his doctor survey supports a "strong" Xpovio launch and long-term outlook.
07/23/19
07/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst John Egbert saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. 2. Murphy Oil (MUR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Singer saying he believes the company's free cash flow generation is being underappreciated by the market. 3. Karyopharm (KPTI) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying he conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months. 4. Smith & Nephew (SNN) upgraded to Buy from Hold at Berenberg with analyst Tom Jones saying he believes management and process changes have addressed the company's execution issues. He views Smith & Nephew's portfolio as "highly competitive." 5. Columbia Sportswear (COLM) upgraded to Buy from Neutral at BofA/Merrill with analyst Alexander Perry citing his outlook for the company to generate "significant near-term revenue and EPS upside" amid a strong wholesale environment for Columbia's apparel as well as its "significant" under-penetration in footwear. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
JPMorgan upgrades Karyopharm after doctor survey, doubles price target
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months, Joseph tells investors in a research note. Importantly, nearly all respondents described the side-effect profile as manageable, which is "very encouraging," adds the analyst. He sees a favorable reward/risk profile for Karyopharm shares at current levels.
BHC Bausch Health
$25.92

1.07 (4.31%)

10/25/19
COWN
10/25/19
INITIATION
Target $35
COWN
Outperform
Bausch Health initiated with an Outperform at Cowen
Cowen analyst Ken Cacciatore initiated coverage of Bausch Health with an Outperform rating as he believes management has successfully transformed and is slowly strengthening its portfolio. The company is also launching new products across the key B&L, Salix, and Dermatological segments while growing its Xifaxan franchise. Cacciatore has a $35 price target on Bausch Health shares.
10/03/19
PIPR
10/03/19
NO CHANGE
Target $29
PIPR
Overweight
Bausch unlikely to face generic Xifaxan before 2028, says Piper Jaffray
Piper Jaffray analyst David Amsellem says he would not be worried that a generic Xifaxan entrant will emerge prior to the January 2028 launch date outlined in Bausch Health Companies' (BHC) settlement with Teva (TEVA) on its generic filing. The analyst highlights the "relatively complex nature" of Xifaxan and Bausch's "fairly deep intellectual property estate." As such, he continues to believe that visibility into a "durable" EBITDA for Bausch Health is high, with a longer-term annual growth "reaching at least the high single digits." He reiterates an Overweight rating on the shares with a $29 price target.
09/17/19
WELS
09/17/19
NO CHANGE
WELS
Underperform
Wells says two of Bausch's 'Significant Seven' not on UnitedHealth benefit list
Wells Fargo analyst David Maris noted that United Healthcare (UNH) released its Pharmacy Benefit Coverage update, which shows that as of January 2020 it is excluding Bausch Health's (BHC) Bryhali, which he said is one of the company's "Significant Seven" focus products. Another of the Significant Seven, Siliq, will no longer be covered under UnitedHealth's pharmacy benefit plans, said Maris. Two other Significant Seven members - Vyzulta and Relistor - are listed as required step therapy and needing a prior authorization, respectively, Maris added. The analyst, who thinks Bausch Health's pipeline and recently approved products are "unimpressive," keeps an Underperform rating on the stock. Reference Link
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Buy
Bausch Health initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders initiated Bausch Health with a Buy rating and a $30 price target, citing the company's strong execution and the durability of its businessses. Flanders believes Bausch will lower its $27B in debt over the next few years, which "should translate to a double-digit compounded equity return for shareholders."
EOLS Evolus
$15.89

(0.00%)

08/13/19
JMPS
08/13/19
NO CHANGE
Target $30
JMPS
Outperform
Evolus price target lowered to $30 from $35 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target on Evolus to $30 after its Q2 earnings miss and to reflect the updated share count for the stock in his valuation model. The analyst is keeping his Outperform rating however, noting that the company's launch of JEUVEAU on May 15 has exceeded expectations on several metrics, including "physician practices joining the JET trial" and patient satisfaction. Ellis maintains his expectation for JEUVEAU to achieve the management's target of a #2 position in the U.S. aesthetic toxin market.
07/31/19
STFL
07/31/19
NO CHANGE
STFL
Buy
Physician survey bodes well for Evolus and Revance, says Stifel
Stifel analyst Annabel Samimy said her survey of 50+ physicians in late June lead her to now believe that new toxins could have penetrations that exceed her current market-share estimates. The survey bodes well for Evolus (EOLS) in the near-term and for both Evolus and Revance (RVNC) in the longer-term while also indicating that Allergan's (AGN) Botox franchise may be more vulnerable than previously thought, Samimy tells investors. She previously had Evolus' Jeuveau reaching a peak market share of 15% and Revance's DaxibotulinumtoxinA reaching 20% shares by 2027, but her new "base case" assumes that Jeuveau peaks at 20% share and Daxi peaks at 25%, noted Samimy, who took down her Botox market share forecast for 2027 to 50%. Samimy raised her price target on Evolus shares to $33 from $30 and keeps a $50 price target on Revance while maintaining Buy ratings on both stocks.
07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
09/05/19
MZHO
09/05/19
INITIATION
Target $30
MZHO
Buy
Evolus assumed with a Buy at Mizuho
Mizuho analyst Difei Yang assumed coverage of Evolus with an unchanged Buy rating and $30 price target. The company's "innovative" Jeuveau neurotoxin will capture significant share in the "attractive" neurotoxin market, Yang tells investors in a research note.
CRNT Ceragon Networks
$2.96

-0.02 (-0.67%)

11/28/18
NEED
11/28/18
DOWNGRADE
NEED
Hold
Ceragon Networks downgraded to Hold from Buy at Needham
11/28/18
NEED
11/28/18
DOWNGRADE
NEED
Hold
Ceragon Networks downgraded to Hold at Needham on valuation
As reported earlier, Needham analyst Alex Henderson downgraded Ceragon Networks to Hold from Buy. The analyst notes that the company has delivered "solid results" and that its stock has benefited from strong execution and expectations of further improvement from 5G build-outs, but believes its valuation reflects the positive news. Henderson further states that the strong growth in Ceragon's India markets in 2018 should pose a challenge to the rate of growth in 2019.
11/28/18
11/28/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Eaton Vance (EV) downgraded to Underweight from Neutral at JPMorgan with analyst Kenneth Worthington saying the company's slowing organic growth will cut into its premium market valuation. 2. CME Group (CME) downgraded to Neutral from Buy at UBS with analyst Alex Kramm saying he believes the current valuation already reflects a higher volatility environment. 3. Ceragon Networks (CRNT) downgraded to Hold from Buy at Needham with analyst Alex Henderson saying the company has delivered "solid results" and that its stock has benefited from strong execution and expectations of further improvement from 5G build-outs, but believes its valuation reflects the positive news. 4. Cracker Barrel (CBRL) downgraded to Underperform from Hold at Gordon Haskett analyst Jeff Farmer saying the share price run-up of 22% over the last 8 weeks is outpacing the company's fundamental prospects. 5. YY (YY) downgraded to Neutral from Overweight at JPMorgan with analyst Alex Yao citing a lack of catalysts for his downgrade of the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TRVN Trevena
$1.01

0.0339 (3.49%)

11/05/18
HCWC
11/05/18
DOWNGRADE
Target $0.75
HCWC
Neutral
Trevena downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Trevena to Neutral and lowered his price target for the shares to 75c from $3.00. Following the Complete Response Letter from the FDA on the new drug application for oliceridin, a second-pass PDUFA date is unlikely until early 2020, Arce tells investors in a research note. He believes the CRL "leaves several open questions."
05/31/19
HCWC
05/31/19
INITIATION
Target $3.5
HCWC
Buy
Trevena assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao assumed coverage of Trevena with a Buy rating and $3.50 price target. The analsut believes the questions raised in the Complete Response Letter appear manageable and that Olinvo has a "clear path to approval." He expects Trevena shares to move higher as the company addresses the items needed to bring Olinvo to market.
09/03/19
HCWC
09/03/19
NO CHANGE
HCWC
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao maiontained a Buy rating and $3.50 price target on Trevena. The analyst noted that Trevena recently announced that it completed enrollment for its ongoing healthy volunteer QT study and remained on track to support topline data readout in Q4. Trevena also said that more than 20 of 30 subjects at that point had received the maximum daily dose of 27mg of oliceridine, a key FDA requirement for the trial. This gives Tsao "confidence that the trial should be successful."
UA Under Armour
$18.91

0.41 (2.22%)

TODAY'S FREE FLY STORIES

MRPLY

Mr Price Group

$0.00

(0.00%)

20:14
12/15/19
12/15
20:14
12/15/19
20:14
Upgrade
Mr Price Group rating change  »

Mr Price Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$341.67

-4.795 (-1.38%)

18:48
12/15/19
12/15
18:48
12/15/19
18:48
Periodicals
Boeing considering halting or cutting 737 MAX production, WSJ reports »

Boeing (BA) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEL

Xcel Energy

$62.27

0.91 (1.48%)

18:42
12/15/19
12/15
18:42
12/15/19
18:42
Initiation
Xcel Energy initiated  »

Xcel Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQUA

Evoqua Water

$19.53

-0.6 (-2.98%)

18:38
12/15/19
12/15
18:38
12/15/19
18:38
Recommendations
Evoqua Water analyst commentary at Stifel »

Evoqua Water price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:33
12/15/19
12/15
18:33
12/15/19
18:33
Upgrade
Bluescope Steel rating change at JPMorgan »

Bluescope Steel upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

16:54
12/15/19
12/15
16:54
12/15/19
16:54
Upgrade
Bluescope Steel rating change at Macquarie »

Bluescope Steel upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$72.82

0.23 (0.32%)

16:36
12/15/19
12/15
16:36
12/15/19
16:36
Recommendations
Stifel adds Sage to Select List, says SAGE-217 will generate billions »

Stifel analyst Paul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DD

DuPont

$64.79

-1.39 (-2.10%)

16:10
12/15/19
12/15
16:10
12/15/19
16:10
Earnings
DuPont sees 2019 operating EBITDA at low end of guidance range »

DuPont reconfirms its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:07
12/15/19
12/15
16:07
12/15/19
16:07
Earnings
IFF affirms existing 2019 guidance for sales and earnings »

IFF is affirming its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:05
12/15/19
12/15
16:05
12/15/19
16:05
Hot Stocks
IFF, DuPont unit see revenue growth in mid-single digits over long term »

The company created by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$103.99

1.085 (1.05%)

, MAT

Mattel

$13.35

0.58 (4.54%)

16:03
12/15/19
12/15
16:03
12/15/19
16:03
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

HAS

Hasbro

$103.99

1.085 (1.05%)

MAT

Mattel

$13.35

0.58 (4.54%)

FNKO

Funko

$15.16

0.23 (1.54%)

JAKK

JAKKS Pacific

$0.94

-0.0244 (-2.54%)

BBW

Build-A-Bear

$2.70

-0.05 (-1.82%)

MAS

Masco

$47.00

-0.44 (-0.93%)

FBHS

Fortune Brands

$65.09

-0.42 (-0.64%)

SPY

SPDR S&P 500 ETF Trust

$317.27

0.13 (0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

IFF

$134.01

-0.55 (-0.41%)

16:03
12/15/19
12/15
16:03
12/15/19
16:03
Hot Stocks
IFF to merge with DuPont's Nutrition & Biosciences unit via Reverse Morris Trust »

IFF (IFF) and DuPont (DD)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:58
12/15/19
12/15
15:58
12/15/19
15:58
Hot Stocks
Breaking Hot Stocks news story on International Flavors, DuPont »

DuPont to receive…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:58
12/15/19
12/15
15:58
12/15/19
15:58
Hot Stocks
Breaking Hot Stocks news story on International Flavors, DuPont »

DuPont holders will own…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$134.01

-0.55 (-0.41%)

, DD

DuPont

$64.79

-1.39 (-2.10%)

15:57
12/15/19
12/15
15:57
12/15/19
15:57
Recommendations
International Flavors, DuPont analyst commentary  »

International Flavors to…

IFF

International Flavors

$134.01

-0.55 (-0.41%)

DD

DuPont

$64.79

-1.39 (-2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILL

Bill.com

$38.59

3.09 (8.70%)

, EH

Ehang

$12.87

0.39 (3.13%)

15:25
12/15/19
12/15
15:25
12/15/19
15:25
On The Fly
Opening Day: XP finishes first week higher, Sprout Social lower »

This past week saw six…

BILL

Bill.com

$38.59

3.09 (8.70%)

EH

Ehang

$12.87

0.39 (3.13%)

HCCO

Healthcare Merger Corp.

$0.00

(0.00%)

OCFT

OneConnect

$10.08

(0.00%)

SPT

Sprout Social

$16.76

(0.00%)

XP

XP

$37.61

3.235 (9.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$67.60

0.285 (0.42%)

, SCOR

comScore

$4.63

-0.41 (-8.13%)

15:09
12/15/19
12/15
15:09
12/15/19
15:09
Hot Stocks
Sony's 'Jumanji' tops weekend box office with $60.1M in sales »

Sony's (SNE)…

SNE

Sony

$67.60

0.285 (0.42%)

SCOR

comScore

$4.63

-0.41 (-8.13%)

DIS

Disney

$146.37

0.4 (0.27%)

LGF.A

Lionsgate

$9.68

-0.315 (-3.15%)

LGF.B

Lionsgate

$9.00

-0.35 (-3.74%)

T

AT&T

$38.24

-0.11 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

DLTR

Dollar Tree

$93.59

1.04 (1.12%)

, DG

Dollar General

$154.75

-0.885 (-0.57%)

14:31
12/15/19
12/15
14:31
12/15/19
14:31
Periodicals
Local governments want dollar stores selling fresh food, WSJ reports »

Local governments across…

DLTR

Dollar Tree

$93.59

1.04 (1.12%)

DG

Dollar General

$154.75

-0.885 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELUXY

Electrolux

$0.00

(0.00%)

14:25
12/15/19
12/15
14:25
12/15/19
14:25
Hot Stocks
Electrolux sees $70M charge in Q4 from North America consolidation »

Electrolux provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$9.74

0.655 (7.21%)

, BP

BP

$36.95

-0.005 (-0.01%)

10:39
12/15/19
12/15
10:39
12/15/19
10:39
Recommendations
Barclays, BP, Amadeus IT Group, Anglo American, BT Group, Carlsberg, Demant, E.ON, Intertek, Novartis, Persimmon, Puma, RSA Insurance, Koninklijke Vopak, Hammerson, NMC Health, Reckitt Benckiser, Renault analyst commentary  »

Jefferies gives European…

BCS

Barclays

$9.74

0.655 (7.21%)

BP

BP

$36.95

-0.005 (-0.01%)

AMADY

Amadeus IT Group

$0.00

(0.00%)

NGLOY

Anglo American

$0.00

(0.00%)

BT

BT Group

$0.00

(0.00%)

CABGY

Carlsberg

$0.00

(0.00%)

WILYY

Demant

$0.00

(0.00%)

EONGY

E.ON

$0.00

(0.00%)

IKTSY

Intertek

$0.00

(0.00%)

NVS

Novartis

$93.00

-0.055 (-0.06%)

PSMMY

Persimmon

$0.00

(0.00%)

PUMSY

Puma

$0.00

(0.00%)

RSNAY

RSA Insurance

$0.00

(0.00%)

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

HMSNF

Hammerson

$0.00

(0.00%)

NMHLY

NMC Health

$0.00

(0.00%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 23

    Mar

SNE

Sony

$67.60

0.285 (0.42%)

, SCOR

comScore

$4.63

-0.41 (-8.13%)

05:55
12/15/19
12/15
05:55
12/15/19
05:55
Hot Stocks
Sony's 'Jumanji' tops weekend box office with $60.1M in sales »

Sony's (SNE)…

SNE

Sony

$67.60

0.285 (0.42%)

SCOR

comScore

$4.63

-0.41 (-8.13%)

DIS

Disney

$146.37

0.4 (0.27%)

LGF.A

Lionsgate

$9.68

-0.315 (-3.15%)

LGF.B

Lionsgate

$9.00

-0.35 (-3.74%)

T

AT&T

$38.24

-0.11 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

, AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

04:55
12/15/19
12/15
04:55
12/15/19
04:55
Conference/Events
Roth Capital to hold a conference »

8th Annual ROTH Deer…

AOBC

American Outdoor Brands

$9.23

-0.04 (-0.43%)

AVCO

Avalon GloboCare

$2.27

-0.06 (-2.58%)

BBSI

Barrett Business

$93.18

1.82 (1.99%)

BNGO

Bionano Genomics

$1.02

0.01 (0.99%)

IRMD

iRadimed

$25.25

-0.52 (-2.02%)

FC

Franklin Covey

$35.21

-0.57 (-1.59%)

NBEV

New Age Beverages

$1.91

-0.015 (-0.78%)

WATT

Energous

$1.99

(0.00%)

EAST

Eastside Distilling

$2.79

-0.12 (-4.12%)

DCTH

Delcath Systems

$0.00

(0.00%)

BOOM

DMC Global

$52.89

0.64 (1.22%)

CLAR

Clarus

$13.47

-0.02 (-0.15%)

JRSH

Jerash Holdings

$6.46

(0.00%)

MCHX

Marchex

$3.68

0.03 (0.82%)

JYNT

Joint Corp.

$17.37

0.28 (1.64%)

SOLY

Soliton

$10.35

-0.005 (-0.05%)

SMSI

Smith Micro

$4.66

0.095 (2.08%)

PWFL

PowerFleet

$6.10

0.05 (0.83%)

OSIS

OSI Systems

$100.60

0.63 (0.63%)

LOVE

Lovesac

$10.80

-1.01 (-8.55%)

VERI

Veritone

$2.73

-0.1 (-3.53%)

WTER

Alkaline Water

$1.09

-0.01 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 29

    Jan

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

, PYPL

PayPal

$107.68

2.01 (1.90%)

13:57
12/14/19
12/14
13:57
12/14/19
13:57
Periodicals
PNC clients having trouble connecting to PayPal's Venmo, WSJ reports »

Many of PNC…

PNC

PNC Financial

$158.60

-0.3 (-0.19%)

PYPL

PayPal

$107.68

2.01 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 15

    Jan

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

, CMCSA

Comcast

$43.59

0.57 (1.33%)

07:44
12/14/19
12/14
07:44
12/14/19
07:44
Periodicals
Berkshire, Anthem among Barron's top 10 stock picks for 2020 »

Barron's has…

BRK.A

Berkshire Hathaway

$338,250.51

-992.49 (-0.29%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

RDS.B

Royal Dutch Shell

$57.41

-0.19 (-0.33%)

RDS.A

Royal Dutch Shell

$57.44

-0.32 (-0.55%)

PFE

Pfizer

$38.31

-0.23 (-0.60%)

VIAC

ViacomCBS

$38.62

0.83 (2.20%)

ANTM

Anthem

$284.14

-0.405 (-0.14%)

DELL

Dell Technologies

$49.39

-0.11 (-0.22%)

GOOG

Alphabet

$1,348.07

-2.09 (-0.15%)

GOOGL

Alphabet Class A

$1,347.11

-1.4 (-0.10%)

UHAL

Amerco

$360.28

7.57 (2.15%)

UTX

United Technologies

$148.99

-0.5 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Feb

PCG

PG&E

$11.26

-0.49 (-4.17%)

07:38
12/14/19
12/14
07:38
12/14/19
07:38
Hot Stocks
California Governor says PG&E restructuring plan 'falls woefully short' »

California Governor Gavin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.